Table 2.
Chemotherapy outcome results, stratified for treatment setting.
| Total | NAIC + RC | 1L chemotherapy | Recurrent disease after RC | 2L chemotherapy | |
|---|---|---|---|---|---|
| Total patients | 96 | 24 | 24 | 34 | 14 |
| eGFR, No. (%) | |||||
| Unknown | 2 (2.1) | 0 (0.0) | 2 (8.3) | 0 (0.0) | 0 (0.0) |
| ≤ 30 mL/min | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 30–60 mL/min | 24 (25.0) | 3 (12.5) | 6 (25.0) | 11 (32.4) | 4 (28.6) |
| ≥ 60 mL/min | 66 (68.8) | 21 (87.5) | 16 (66.7) | 21 (61.8) | 8 (57.1) |
| Type of chemotherapy, No. (%) | |||||
| Gemcitabine/Cisplatin | 51 (53.1) | 20 (83.3) | 11 (45.8) | 16 (47.1) | 4 (28.6) |
| Gemcitabine/Carboplatin | 36 (37.5) | 4 (16.7) | 13 (54.2) | 16 (47.1) | 3 (21.4) |
| Docetaxel | 9 (9.4) | 0 (0.0) | 0 (0.0) | 2 (5.9) | 7 (50.0) |
| Treatment adjustments, No. (%) | |||||
| Dose reduction | 47 (49.0) | 6 (25.0) | 17 (70.8) | 20 (58.8) | 4 (28.6) |
| Early termination | 35 (36.5) | 5 (20.8) | 10 (41.7) | 13 (38.2) | 7 (50.0) |
| Carboplatin switch | 9 (9.4) | 3 (12.5) | 2 (8.3) | 2 (5.9) | 2 (14.3) |
| Full treatment received | 22 (22.9) | 12 (50.0) | 3 (12.5) | 6 (17.6) | 1 (7.1) |
| Best response, No. (%) | |||||
| cPD (clinical progressive disease) | 34 (38.2) | 6 (25.0) | 6 (27.3) | 13 (41.9) | 9 (75.0) |
| cSD (clinical stable disease) | 8 (9.0) | 2 (8.3) | 1 (4.5) | 5 (16.1) | 0 (0.0) |
| cPR (clinical partial response) | 39 (43.8) | 15 (62.5) | 11 (50.0) | 10 (32.3) | 3 (25.0) |
| cCR (clinical complete response) | 8 (9.0) | 1 (4.2) | 4 (18.2) | 3 (9.7) | 0 (0.0) |
| Unknown | 7 | 0 | 2 | 3 | 2 |
| CTCAE complication*, No. (%) | |||||
| Grade 3 | 49 (54.4) | 8 (36.4) | 11 (45.8) | 21 (70.0) | 9 (64.3) |
| Grade 4 | 8 (8.9) | 3 (13.6) | 3 (12.5) | 2 (6.7) | 0 (0.0) |
| Grade 5 | 4 (4.4) | 1 (4.5) | 2 (8.3) | 0 (0.0) | 1 (7.1) |
| Unknown | 6 | 2 | 0 | 4 | 0 |
| Need for blood transfusion, No. (%) | 34 (35.4) | 2 (8.3) | 9 (37.5) | 16 (47.1) | 7 (50.0) |
| Median follow-up [95% CI] | 58.9 [33.1–84.8] | 58.9 [27.0–90.9] | 32.9 N.D.** | 50.9 [20.2–81.7] | N.D.** |
| Median overall survival (OS) [95% CI] | 10.2 [7.2–13.2] | 19.5 [0.0–49.1] | 12.6 [8.8–16.4] | 7.5 [0.0–15.6] | 6.6 [4.7–8.4] |
| Median progression-free survival (PFS) [95% CI] | 5.6 [4.1–7.1] | 9.5 [0.7–18.3] | 6.1 [0.0–14.1] | 3.5 N.D.** | 0.0 N.D.** |
NAIC Neoadjuvant/induction chemotherapy, RC radical cystectomy, 1L first-line, 2L second-line, CTCAE common terminology criteria for adverse events, 95% CI 95% confidence interval.
*Maximum grade CTCAE complication that patients suffered.
**Median follow-up and 95% CI could not be determined.